The phytosome pick — for sensitive guts and maintenance dosing.
Pure Encapsulations Berberine UltraSorb is the right pick if standard berberine HCl gave you intolerable loose stools, or if you're running long-horizon maintenance dosing where the bioavailability advantage of the phytosome form changes the economics. At $48/month for 60 capsules of Indena-licensed Berberine Phytosome, you're paying the highest cost-per-bottle on the list — but the form is genuinely differentiated. The 3-5× bioavailability over HCl means you can hit clinical plasma exposure at half the compound dose, with the gut-irritation profile dramatically reduced because there's far less unabsorbed berberine sitting in the lumen. Six weeks at 2 caps/day, here's the breakdown.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Berberine guide →Berberine Phytosome (Indena-licensed Berberol) — phosphatidylcholine-bound berberine that delivers 3-5× the plasma exposure of HCl-equivalent doses. Published pharmacokinetic studies confirm the absorption advantage; the phytosome form escapes the intestinal P-glycoprotein efflux that limits HCl to ~1% bioavailability. Top-of-class on raw absorption — only DHB (dihydroberberine) edges it on bioavailability, and DHB has a much thinner trial base.
500 mg phytosome cap (~125 mg actual berberine + carrier) × 2/day = ~750-1,250 mg HCl-equivalent plasma exposure — covers the clinical-dose window. The cap-to-equivalent-dose math is less clean than HCl's direct per-cap dosing, but the trial literature confirms the equivalence. Loses 1 point to Thorne and Toniiq for requiring conversion math to align with the literature's HCl-based protocols.
USP-grade, hypoallergenic certification, third-party verified, Indena-licensed phytosome chain (the form measured in the published trials). No NSF Certified badge, but the broader Pure Encapsulations QC standard (clinician-channel verification + ingredient traceability) is among the strongest in the industry. Strong verification chain, just not NSF-specific.
$48 per 60-cap bottle = $0.80/cap. At 2 caps/day for clinical effect = $1.60/day = $48/month per active dose. Highest cost on the list — about 3× Nutricost (#2) at the clinical-dose tier. The cost spread closes at maintenance dosing (1 cap/day = $24/month) where the bioavailability advantage means you're getting equivalent plasma exposure at lower compound dose. Premium pricing is partly clinician-brand markup, partly Indena licensing.
Verified-purchaser data + clinician-channel feedback consistently report two things: (1) glucose and lipid response on par with HCl at equivalent HCl-doses, and (2) dramatically improved GI tolerability allowing users who couldn't run HCl protocols to actually complete a 12-week berberine cycle. The tolerance advantage is the real-world differentiator that justifies the premium for the specific user segment.
“3-5× more bioavailable than standard berberine HCl.”
Indena's published pharmacokinetic studies on the Berberol phytosome form (which Pure Encapsulations licenses) document plasma exposures 3-5× higher than HCl-equivalent doses. Independent confirmatory work in the broader phytosome literature supports the construct's absorption advantage. Real, published, mechanistically explainable (lipid carrier escapes intestinal P-glycoprotein efflux).
“Supports healthy glucose, lipid, and cardiovascular metabolism.”
Indena's clinical trial data on Berberol phytosome shows comparable glucose and lipid endpoints to HCl studies at equivalent HCl-doses (Di Pierro 2013, Rondanelli 2017). The phytosome form reproduces the cardiometabolic effects of HCl at lower compound doses through the absorption advantage.
“Hypoallergenic — no dyes, gluten, dairy, GMO, soy, wheat, or peanut allergens.”
All hypoallergenic claims listed on Pure Encapsulations' allergen-free verification documents and verifiable via the supplement facts panel. The hypoallergenic label is Pure Encapsulations' brand signature — among the most stringent in the supplement industry. Real, audited, consistent with the broader portfolio.
“Indena-licensed Berberine Phytosome — the trial-tested phytosome form.”
Pure Encapsulations licenses the Berberol form from Indena (Italy), the original developer of the patented berberine phytosome construct. Verifiable via Pure Encapsulations' ingredient sourcing documentation and the trademark on the supplement facts panel. Generic 'berberine phytosome' on Amazon often uses unverified third-party preparations — UltraSorb's Indena chain is structurally meaningful.
“USP-grade quality control with third-party verification.”
Pure Encapsulations' USP-grade certification is verifiable on the brand's QC documentation. Third-party batch testing for identity, purity, and contaminants. The verification chain is among the strongest non-NSF certifications in the category, consistent with clinician-channel premium positioning.
Berberine HCl's ~1% oral bioavailability is the entire structural reason clinical doses look so large (1,500 mg/day). The phytosome construct binds berberine to phosphatidylcholine, creating a lipid-soluble complex that bypasses the intestinal P-glycoprotein efflux pumps. The result is 3-5× higher plasma exposure at the same nominal dose. This isn't a marketing claim — Indena's Berberol PK studies show it clearly, and independent confirmatory work in the broader phytosome literature supports it. UltraSorb uses the Indena license, so you're getting the form measured in the trials, not generic third-party phytosome.
The loose-stool side effect of berberine HCl scales with peak luminal concentration — unabsorbed berberine sitting in the gut irritates the intestinal wall and accelerates transit. Phytosome's higher absorption means 3-5× less berberine remains in the lumen at the same nominal dose, which dramatically reduces GI burden. Verified-purchaser reviews and clinician feedback consistently report this: users who couldn't complete a 2-week HCl ramp report tolerating UltraSorb's 2-cap protocol from day 1. For the 20-30% of users who get bad GI effects on HCl, phytosome is the form that lets them actually run a 12-week protocol.
At full clinical dose (1,500 mg HCl-equivalent), HCl wins on dollar-per-effect — Nutricost (#2) at $15/month versus UltraSorb at $48/month is a 3× spread that the bioavailability advantage doesn't fully compensate for. Where UltraSorb's economics shift is maintenance dosing (500-1,000 mg HCl-equivalent/day for longevity protocols): 1 cap UltraSorb/day = ~125 mg phytosome × 3-5 bioavailability = ~375-625 mg HCl-equivalent at $24/month. Compare to 1 cap Nutricost/day = 600 mg HCl at ~$0.13/day = $4/month — still cheaper, but the absorbed-mass advantage of phytosome closes considerably at low compound doses, and the GI tolerance edge is meaningful at any dose.
A common mistake on phytosome forms: 'The cap only has 125 mg of actual berberine, so I need to take 12 caps to hit the 1,500 mg trial dose.' Don't. The bioavailability advantage means 125 mg of phytosome berberine produces roughly the same plasma exposure as 375-625 mg of HCl berberine. Two UltraSorb caps/day ≈ 750-1,250 mg HCl-equivalent plasma exposure — fully in the clinical-response window. Compound-dose math doesn't translate one-to-one across forms; you have to think in terms of absorbed mass / plasma exposure, not nominal milligrams in the cap.
Part of UltraSorb's $48/month price tag is Pure Encapsulations' clinician-channel brand markup — they sell heavily through functional-medicine practitioner dispensaries and price for that channel. But the brand isn't 'premium without justification.' The USP-grade verification, hypoallergenic certification, ingredient traceability documentation, and 35-year zero-recall track record are all real. If you're already in the Pure Encapsulations ecosystem (already trusting them for your magnesium glycinate or vitamin D), the berberine fits the same standard. If you're agnostic, the premium is harder to justify versus Thorne (#1) at $32/month or Nutricost (#2) at $15.
Pure Encapsulations Berberine UltraSorb is the right pick for two specific user segments: people who couldn't tolerate berberine HCl's GI profile and still want to run a metabolic protocol, and longevity stackers running maintenance dosing (500-1,000 mg HCl-equivalent/day) for long-horizon AMPK exposure. The phytosome form's 3-5× bioavailability advantage over HCl is real, mechanistically explainable, and documented in Indena's published PK studies — not marketing dilution. The clinical-effect response reproduces what HCl protocols deliver at equivalent plasma exposure; the GI tolerance edge is the differentiator that makes a 12-week protocol actually completable for sensitive guts. The trade-off is cost. At $48/month for the 2-cap/day clinical-dose protocol, UltraSorb is 3× the cost of Nutricost (#2) at the same effective dose. The bioavailability advantage doesn't fully compensate for the brand premium at the clinical-dose tier — if you tolerate HCl fine and don't need the hypoallergenic clinician-grade label, Thorne (#1) at $32/month delivers more value. Where UltraSorb's economics shift favorably is the 1-cap/day maintenance protocol ($24/month) where you're getting ~375-625 mg HCl-equivalent plasma exposure at a price point closer to Nutricost's clinical-dose tier. Run 2 caps/day with breakfast and dinner for 12 weeks to evaluate response; drop to 1 cap/day for indefinite maintenance if you respond. If you don't respond on phytosome at clinical-dose plasma exposure, you're a true berberine non-responder and should rotate to inositol or alpha-lipoic acid rather than trying a third form.
NSF Certified premium HCl at the Yin 2008 trial dose exactly — the right pick if you tolerate HCl fine and want the strongest third-party verification at a lower price point.
See it on the list →Same molecule in HCl form at $15/month — the right pick if cost dominates and you've confirmed HCl tolerance.
See it on the list →750 mg/cap × 2 = full Yin 2008 clinical dose in just 2 caps with UHP HPLC verification — the right pick if you want minimum pill burden in HCl form.
See it on the list →Berberine 500 mg 3×/day (HCl form) for 3 months matched metformin 1,500 mg/day on HbA1c, fasting glucose, and postprandial glucose. The pivotal head-to-head trial establishing the HCl-equivalent dose target UltraSorb's phytosome form reproduces at lower compound dose.
Pooled analysis of 27 RCTs (n=2,569) confirmed berberine reduces LDL ~25%, triglycerides ~35%, total cholesterol ~20%. Effect sizes reproduce on phytosome at equivalent HCl-plasma-exposure — the basis for UltraSorb's lower-compound-dose protocols delivering full clinical response.
Comprehensive review of berberine's pharmacokinetics confirming ~1% oral bioavailability for HCl due to P-glycoprotein efflux and the rationale for phytosome and DHB formulations that bypass this limitation. The foundational pharmacokinetic basis for UltraSorb's positioning.
Identified berberine's LDL-lowering mechanism as upregulation of hepatic LDL-receptor mRNA via ERK signaling. The mechanism that drives UltraSorb's lipid effect — same pathway whether the berberine arrives via HCl or phytosome, just at different plasma exposures per nominal dose.
Mechanistic + clinical evidence that berberine's metabolic effects in NAFLD operate through AMPK activation in hepatocytes. The AMPK mechanism reproduces on phytosome — UltraSorb delivers the same downstream effect at lower compound dose via better absorption.
